Get all your news in one place.

100’s of premium titles.
One app.

Start reading

Get all your news in one place.

100’s of premium titles. One news app.

Start reading

The Latest Breaking News from ALNY

Why Is Alnylam Pharmaceuticals Stock Trading Lower Thursday?

Alnylam Pharmaceuticals Inc. (NASDAQ:ALNY) stock is trading lower after the company reported third-quarter earnings.

Benzinga

Profits May Be Just Around the Corner for This Strong-Buy Pharma Stock

Alnylam Pharmaceuticals (ALNY) shows strong price momentum, hitting new all-time highs on Aug. 11. ALNY has a 100% technical “Buy” opinion via Barchart. The company boasts a robust pipeline, recent FDA approvals, and dramatic projected revenue and earnings growth for 2025. Analyst sentiment is mostly bullish with high price targets....

Barchart

This Alnylam Pharmaceuticals Analyst Is No Longer Bearish; Here Are Top 5 Upgrades For Monday

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page.

Benzinga

From analysis to the latest developments in health,
read the most diverse news in one place.

Alnylam's Amvuttra Makes Powerful Entrance, Eyes First-Line Dominance

Alnylam Pharmaceuticals Inc. (NASDAQ:ALNY) reported upbeat second-quarter earnings and 2025 guidance on Thursday.

Benzinga

Alnylam Pharmaceuticals Q2 Earnings Crush Estimates, Stock Hits 52-Week High On Upbeat Forecast

The biotechnology sector is witnessing a surge in investor optimism as companies like Alnylam Pharmaceuticals Inc. (NASDAQ:ALNY) continue to outperform market expectations. Amid a backdrop of growing demand for innovative treatments, Alnylam’s recent performance highlights the company’s strong position in the competitive landscape.

Benzinga

This Alnylam Pharmaceuticals Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday

Benzinga

3 Biotech Stocks to Watch as FDA Approvals Roll In

The biotech sector is booming, fueled by rising healthcare demands, exciting advancements in technology, and increased FDA drug approvals. Thus, investing in Illumina (ILMN), Alnylam Pharmaceuticals (ALNY), and Gilead Sciences (GILD) could be a golden opportunity for those looking to ride the wave of future breakthroughs. Read on….

StockNews.com

Read news from The Economist, FT, and more,
with one subscription

3 Genomics Stocks Transforming Healthcare

Genomics is on the brink of revolutionizing healthcare with breakthroughs that could redefine treatment and diagnosis. As this field rapidly evolves, investing in fundamentally sound genomics stocks like Regeneron Pharmaceuticals (REGN), Alnylam Pharmaceuticals (ALNY), and Illumina (ILMN) could be beneficial. Read more….

StockNews.com

3 Biopharma Stocks to Buy for Long-Term Growth

With the rising investment in personalized medicine research and development and growing clinical trials, the biopharma industry’s prospects appear promising. Hence, quality biotech stocks, Alnylam Pharmaceuticals (ALNY), Illumina (ILMN), and Gilead Sciences (GILD) with long-term growth might be solid buys. Read more….

StockNews.com

3 Biotech Stocks With Sky-High Price Targets

The biotech sector is primed for growth, fueled by numerous advancements in genetic engineering and rising investment in research and development of personalized medicine. Hence, quality biotech stocks, BioMarin Pharmaceutical (BMRN), Alnylam Pharmaceuticals (ALNY), and Corcept Therapeutics (CORT) with sky-high price targets might be solid buys. Read more….

StockNews.com

3 Biotech Stocks Paving the Way for Bullish Investment Gains

The biotech industry is rapidly expanding due to the popularity of personalized medicines and novel therapies, government initiatives, and technological adoption. Hence, quality biotech stocks Alnylam Pharmaceuticals (ALNY), Dynavax Technologies (DVAX), and Innoviva (INVA) could pave the way for substantial gains. Read more….

StockNews.com

Are These 3 Biotech Stocks Poised for 2024 Growth?

The biotech industry is well-positioned for solid growth thanks to the increasing demand for effective treatments for chronic diseases, a rapidly aging population, the adoption of technologies like AI, and government initiatives. To capitalize on the biotech industry’s growth prospects, should one consider investing in biotech stocks Puma Biotechnology (PBYI),…

StockNews.com

Will These 3 Biotech Stocks Make Gains in 2024?

In the swiftly progressing arena of biotechnology, technological advancements, increasing merger and acquisition maneuvers, and developing product pipelines are driving significant expansion in this sector. The sector's strong potential is further reinforced by a steady demand, ensuring its sustenance. Given this backdrop, let’s analyze whether or not biotech stocks Illumina…

StockNews.com

3 Biotech Stocks to Buy for Your 2024 Portfolio

The biotech industry is thriving amid innovation, demand, adaptability, and technological advancements, demonstrating resilience and adaptability. So, it could be wise to invest in quality biotech stocks Protalix BioTherapeutics (PLX), Alnylam Pharmaceuticals (ALNY), and Jazz Pharmaceuticals (JAZZ). Read on.

StockNews.com

Get all your
news in one place.

100’s of premium titles.
One news app.

StockNews.com

3 Solid Biotech Buys for a Healthy Year-End Portfolio

The growing adoption of AI technologies by biopharmaceutical companies and the increasing government initiatives worldwide are expected to boost the biotech industry. Therefore, it could be wise to buy fundamentally strong biotech stocks Innoviva (INVA), Genmab (GMAB), and Alnylam Pharmaceuticals (ALNY) for a healthy year-end portfolio. Read more.

Benzinga

Alnylam's Lumasiran Shows Clinical Benefit In Rare Kidney Disease

Alnylam Pharmaceuticals Inc (NASDAQ:ALNY) announced new results from the six-month primary analysis of the ILLUMINATE-C Phase 3 open-label study of lumasiran for primary hyperoxaluria type 1 (PH1). PH1 is a rare disorder that mainly affects the kidneys. It results from the buildup of a substance called oxalate, typically filtered through the kidneys and…

Benzinga

Alnylam Pharmaceuticals Earnings Perspective: Return On Capital Employed

According to data from Benzinga Pro, during Q1, Alnylam Pharmaceuticals's (NASDAQ:ALNY) reported sales totaled $213.26 million. Despite a 7.01% increase in earnings, the company posted a loss of $240.34 million.

Benzinga

Expert Ratings for Alnylam Pharmaceuticals

Over the past 3 months, 10 analysts have published their opinion on Alnylam Pharmaceuticals (NASDAQ:ALNY) stock. These analysts are typically employed by large Wall Street banks and tasked with understanding a company's business to predict how a stock will trade over the upcoming year.

Get all your
news in one place.

100’s of premium titles.
One news app.

Benzinga

Recap: Alnylam Pharmaceuticals Q1 Earnings

Alnylam Pharmaceuticals (NASDAQ:ALNY) reported its Q1 earnings results on Thursday, April 28, 2022 at 08:00 AM. Here's what investors need to know about the announcement.

Benzinga

What To Know About Morgan Stanley's Downgrade of Alnylam Pharmaceuticals

Morgan Stanley downgraded its rating of Alnylam Pharmaceuticals (NASDAQ:ALNY) to Equal-Weight with a price target of $178.00, changing its price target from $210.00 to $178.00. Shares of Alnylam Pharmaceuticals are trading down 4.47% over the last 24 hours, at $159.53 per share.

Benzinga

See Why Did FDA Extend Review Period For Alnylam's Vutrisiran In Amyloidosis

The FDA has extended the review timeline for Alnylam Pharmaceuticals Inc's (NASDAQ:ALNY) marketing application for vutrisiran for transthyretin-mediated (ATTR) amyloidosis. The updated Prescription Drug User Fee Act (PDUFA) goal date is July 14. The FDA needs additional time to review newly added information related to the new secondary packaging and labeling facility for investigational RNAi…

Benzinga

What 8 Analyst Ratings Have To Say About Alnylam Pharmaceuticals

Within the last quarter, Alnylam Pharmaceuticals (NASDAQ:ALNY) has observed the following analyst ratings:

Benzinga

Looking Into Alnylam Pharmaceuticals's Return On Capital Employed

Benzinga Pro data, Alnylam Pharmaceuticals (NASDAQ:ALNY) reported Q4 sales of $258.54 million. Earnings fell to a loss of $258.46 million, resulting in a 26.38% decrease from last quarter.

Benzinga

Expert Ratings For Alnylam Pharmaceuticals

Analysts have provided the following ratings for Alnylam Pharmaceuticals (NASDAQ:ALNY) within the last quarter:

Benzinga

Alnylam Clocks 76% Increase In Q4 Product Sales, Expects FY22 Product Sales Of Up To $1B

Alnylam Pharmaceuticals Inc's (NASDAQ: ALNY)

1 2

People

Sristi Suman JayaswalThe

216 stories

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

European Medicines Agency

Regeneron Pharmaceuticals Inc

45 stories

Grail

44 stories

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.